(Q33988445)

30 July 2017

Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial (English)

1 reference

30 July 2017

phase III clinical trial

0 references

0 references

1 reference

3

Ritsuko Komaki

1 reference

30 July 2017

4

Roy S Herbst

1 reference

30 July 2017

Charles Lu

1

1 reference

30 July 2017

J Jack Lee

2

1 reference

30 July 2017

Lei Feng

5

1 reference

30 July 2017

William K Evans

6

1 reference

30 July 2017

Hak Choy

7

1 reference

30 July 2017

Pierre Desjardins

8

1 reference

30 July 2017

Benjamin T Esparaz

9

1 reference

30 July 2017

Mylene T Truong

10

1 reference

30 July 2017

Scott Saxman

11

1 reference

30 July 2017

Joseph Kelaghan

12

1 reference

30 July 2017

Archie Bleyer

13

1 reference

30 July 2017

Michael J Fisch

14

1 reference

30 July 2017

language of work or name

English

0 references

publication date

26 May 2010

1 reference

Journal of the National Cancer Institute

30 July 2017

1 reference

30 July 2017

102

1 reference

30 July 2017

12

1 reference

30 July 2017

859-865

1 reference

Targeting angiogenesis in the treatment of lung cancer

30 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2902826

5 July 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2902826

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2902826

Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2902826

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2902826

Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2902826

Neovastat--a novel antiangiogenic drug for cancer therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2902826

The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2902826

Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2902826

5 July 2018

The Hallmarks of Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2902826

The prevalence of complementary/alternative medicine in cancer: a systematic review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2902826

Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2902826

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2902826

Reporting results of cancer treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2902826

Phase I/II Trial of the Safety and Efficacy of AE-941 (Neovastat®) in the Treatment of Non–Small-Cell Lung Cancer

5 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ179

Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ179

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ179

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ179

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ179

The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2902826

Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2902826

Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20505152

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/JNCI/DJQ179

1 reference

30 July 2017

1 reference

30 July 2017

1 reference